SCN9A rs121908488: What Your Genotype Means
The rs121908488 variant is a rare genetic change located within the SCN9A gene. It is associated with autosomal dominant painful channelopathies, including primary erythromelalgia and paroxysmal extreme pain disorder.
What each genotype means
Typical SCN9A profile
This genotype represents the most common sequence found in the general population for this location in the SCN9A gene. It is not associated with the rare, gain-of-function painful channelopathies linked to this variant. No specific clinical action is indicated based on this result.
This is the predominant genotype observed across all major global populations.
Potential carrier status
This genotype indicates the presence of one copy of the variant allele. While some SCN9A variants are linked to autosomal dominant conditions like primary erythromelalgia or paroxysmal extreme pain disorder, the clinical significance of this specific variant can be complex and may require correlation with your personal and family medical history. Please discuss these results with a genetic counselor or your healthcare provider to understand if this finding is relevant to your health.
This genotype is rare, occurring at a very low frequency in the general population.
Rare variant genotype
This genotype indicates the presence of two copies of the variant allele. Because this variant is linked to rare, inherited pain syndromes, this result warrants clinical review to determine if it correlates with any symptoms or family history of pain disorders. You should consult with a medical professional or genetic specialist to interpret this finding in the context of your overall health.
This genotype is extremely rare and is not typically observed in the general population.
Understanding the SCN9A Gene
The SCN9A gene provides the essential instructions for building the alpha subunit of a voltage-gated sodium channel known as NaV1.7. These channels act like tiny gates on the surface of nerve cells, controlling the flow of sodium ions into the cell. This process is critical for the generation and transmission of electrical signals, particularly in neurons responsible for sensing pain and touch. Because NaV1.7 is highly expressed in the peripheral nervous system, it plays a central role in how our bodies process nociception, or the sensation of pain. When the gene functions normally, it helps maintain the delicate balance of electrical excitability required for healthy nerve signaling. However, because this channel is so specialized for pain pathways, even minor alterations in its structure can lead to significant changes in how pain signals are triggered or amplified.
What is the rs121908488 Variant?
The rs121908488 variant is a specific change in the DNA sequence of the SCN9A gene. In the context of genetic research, this variant is categorized as a missense mutation, meaning it results in a single amino acid substitution within the NaV1.7 protein. This change can alter the biophysical properties of the sodium channel, often leading to a 'gain-of-function' effect. In many documented cases, such mutations prevent the channel from closing properly or lower the threshold required to trigger an electrical impulse. This results in neurons that are hyper-excitable, meaning they fire pain signals more easily or more frequently than they should. Because this variant is linked to inherited conditions, it is typically studied in the context of how these altered channels contribute to chronic, episodic, or severe pain syndromes that run in families.
Research and Clinical Associations
Scientific research has established a strong link between SCN9A variants and a spectrum of painful channelopathies. The rs121908488 variant is specifically associated with conditions like primary erythromelalgia, which is characterized by intense burning pain, redness, and increased skin temperature in the extremities, often triggered by heat or exercise. It is also linked to paroxysmal extreme pain disorder, a condition involving sudden, severe episodes of pain in specific body regions. The evidence for these associations is considered moderate to strong in clinical literature, as functional studies have demonstrated that these mutations lead to persistent sodium currents or altered activation thresholds. While these findings are significant, it is important to note that the clinical expression of these variants can be highly variable, even among family members who carry the same genetic change, suggesting that other genetic or environmental factors may influence the severity of symptoms.
Population Frequency and Interpretation
The rs121908488 variant is classified as rare in the general population. Because it is not a common polymorphism found in the majority of people, it is typically identified through clinical genetic testing in individuals who are already experiencing symptoms of a suspected channelopathy. Its rarity means that large-scale population studies have limited data on its exact frequency across different global ancestries. When a clinician identifies this variant, it is usually in the context of a diagnostic workup for unexplained chronic pain. It is vital to understand that the presence of this variant does not automatically guarantee a specific clinical outcome, as the penetrance and expressivity of such mutations can differ significantly between individuals. Genetic information should always be interpreted by a qualified medical professional who can correlate the findings with a patient's specific clinical history and physical symptoms.
Managing Genetic Information
If you or a family member have been identified as a carrier of an SCN9A variant, it is important to approach this information with the guidance of a genetic counselor or a neurologist specializing in pain disorders. You cannot use this information to self-diagnose or predict the exact course of a condition. Because some SCN9A-related conditions respond to specific medications, such as sodium channel blockers, it is essential to discuss any potential treatment options or medication adjustments with your clinician or pharmacist. They can help determine if a specific therapy is appropriate based on your unique genetic profile and clinical presentation. Avoid making changes to your health regimen based solely on genetic reports. Instead, use this information as a tool to facilitate a more informed conversation with your healthcare team, ensuring that your care plan is tailored to your specific medical needs.
How common is this variant?
The rs121908488 variant is rare in the general population, with its frequency typically documented as very low across all major ancestral groups.
Frequently asked questions
What is an SCN9A-related pain disorder?
An SCN9A-related pain disorder is a condition caused by mutations in the SCN9A gene, which affects the function of NaV1.7 sodium channels. These conditions, such as erythromelalgia, result in abnormal pain signaling in the nervous system.
Can I be tested for the rs121908488 variant?
Yes, genetic testing for specific SCN9A variants is available through clinical laboratories, usually ordered by a neurologist or geneticist. You should discuss the necessity and implications of such testing with your doctor.
Are there treatments for SCN9A mutations?
Some patients with SCN9A-related pain may be treated with medications that block sodium channels, such as carbamazepine. Always consult your clinician or pharmacist to discuss if any medication is appropriate for your specific case.
Does having this variant mean I will definitely have pain?
Not necessarily. While this variant is associated with pain disorders, the way it manifests can vary greatly between individuals. Factors like other genes and environmental triggers play a role in how the condition presents.
Sources & further reading
Educational information only, last refreshed 10/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908488?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SCN9A
This voltage-gated sodium channel variant modulates nociceptive sensitivity, causing carriers to exhibit higher pain thresholds across various sensory modalities.
A pathogenic variant in SCN9A linked to paroxysmal extreme pain disorder, relevant for carrier screening in hereditary pain syndromes.
This variant in the SCN9A gene is associated with autosomal dominant painful channelopathies, including primary erythromelalgia.